• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

11.90 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 103
Open 11.90
Bid (Size) 11.50 (100)
Ask (Size) 12.10 (200)
Prev. Close 11.90
Today's Range 11.90 - 11.90
52wk Range 9.820 - 20.22
Shares Outstanding 60,069,512
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Trevi Therapeutics Q2 Earnings Call Highlights ↗
August 07, 2026
Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,... 
Via MarketBeat
Topics Earnings
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
June 03, 2026
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

52-Week Range 41.1% below 52-week high
11.90
9.8252W Low 20.2252W High
1 Week 9.8% below 1-week high
11.701W Low 13.191W High

Trevi Therapeutics, Inc. - Common Stock (TRVI) traded between $9.82 and $20.22 over the past 52 weeks and last traded at $11.90, 41.1% below its 52-week high. Over the past week it ranged between $11.70 and $13.19.

Past 12 Months
-3.2%
-20.1%
-29.0%
-22.7%
+0.1%
+11.3%
1W -$0.39
1M -$2.99
3M -$4.87
6M -$3.50
YTD +$0.01
1Y +$1.21

TRVI was +11.3% over the past year, -22.7% over six months, +0.1% year to date, -3.2% in the last week.

12 Months vs Market
TRVI
+11.3%
DIA
+11.1%
SPY
+14.2%
QQQ
+17.5%
IWM
+9.3%

Over the past 12 months TRVI returned +11.3% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 0.00× 3-mo avg
Today 103 3-mo avg 2.0M
1W
2.1M
1M
2.8M
3M
2.0M
6M
2.0M
YTD
1.8M
1Y
1.8M

TRVI most recently traded 103 shares against a 3-month average daily volume of 2.0M.

More News

Read More
News headline image
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 ↗
May 09, 2026
Via MarketBeat
Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Program ↗
March 17, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
November 13, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
May 08, 2025
Via Benzinga
News headline image
Earnings Preview For Trevi Therapeutics ↗
May 07, 2025
Via Benzinga
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
March 23, 2026
Via The Motley Fool
News headline image
Trevi Therapeutics (TRVI) Earnings Transcript ↗
March 18, 2026
Via The Motley Fool
News headline image
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns ↗
March 09, 2026
Via Stocktwits
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
December 22, 2025
Via MarketBeat
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
December 03, 2025
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
November 28, 2025
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
November 27, 2025
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
November 27, 2025
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
November 27, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗
November 13, 2025
Via Chartmill
News headline image
A Peek at Trevi Therapeutics's Future Earnings ↗
November 12, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 03, 2025
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
September 09, 2025
Via Benzinga
News headline image
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
August 21, 2025
Via Benzinga
News headline image
Dow Gains Over 100 Points; US Job Openings Increase In April ↗
June 03, 2025
Via Benzinga
Topics Stocks
News headline image
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗
June 02, 2025
Via Benzinga
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
From Avalo Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Trevi Therapeutics, Inc. - Common Stock publicly traded?
Yes, Trevi Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Trevi Therapeutics, Inc. - Common Stock trade on?
Trevi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Trevi Therapeutics, Inc. - Common Stock?
The ticker symbol for Trevi Therapeutics, Inc. - Common Stock is TRVI on the Nasdaq Stock Market
What is the current price of Trevi Therapeutics, Inc. - Common Stock?
The current price of Trevi Therapeutics, Inc. - Common Stock is 11.90
When was Trevi Therapeutics, Inc. - Common Stock last traded?
The last trade of Trevi Therapeutics, Inc. - Common Stock was at 10/19/26 04:00 PM ET
What is the market capitalization of Trevi Therapeutics, Inc. - Common Stock?
The market capitalization of Trevi Therapeutics, Inc. - Common Stock is 714.83M
How many shares of Trevi Therapeutics, Inc. - Common Stock are outstanding?
Trevi Therapeutics, Inc. - Common Stock has 715M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap